'Stage iiib' diaporamas de présentation

GYN GEC-ESTRO /ICRU Target Concept

518 views • 49 slides

Department of Thoracic/Head & Neck

Mutational Analysis in NSCLC Adenocarcinoma to Guide Therapy. Anne S. Tsao, M.D. Associate Professor. Director, Mesothelioma Program Director, Thoracic Chemo-XRT Program. The University of Texas. Department of Thoracic/Head & Neck. MD ANDERSON. Medical Oncology. CANCER CENTER.

602 views • 45 slides

Maintenance therapy for NSCLC

Maintenance therapy for NSCLC. Istituto Toscano Tumori-Livorno-Italy. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile Livorno-Italy. The maintenance therapy paradigm. No progression after 4 cycles of platinum-based CT, PS=0-1.

553 views • 35 slides

???? ??? ? ? ? ( Chest Surgery Associated Professor Kao Eing-Long ) Tel: 3121101 ext: 6306

?????? ( Respiratory Disease ). ?????? ( Non Small Cell Lung Cancer ). ???? ??? ? ? ? ( Chest Surgery Associated Professor Kao Eing-Long ) Tel: 3121101 ext: 6306 E mail: kaeil@cc.kmu.edu.tw. ???? ( Learning Object ). Classification of Lung Cancer : SCLC vs NSCLC.

427 views • 34 slides

460 views • 34 slides

355 views • 34 slides

348 views • 34 slides

Chandra P Belani, MD Deputy Director Penn State Cancer Institute

328 views • 25 slides

JCM OSCE Answer

JCM OSCE Answer. POH A&E 4 th June, 2014. Question 1. 44/M Construction worker Neck injury after accidentally fell from 3m of height Complained with 4 limbs weakness CT C-spine was taken. Question 1. Question 1. Describe the CT findings .

347 views • 24 slides

Air Quality and The London Plan

Air Quality and The London Plan. Celeste Giusti Senior Strategic Planner. Introduction. Air quality in London The London Plan Strategic LDF preparation Decisions Design measures Air quality assessments Air quality neutral Emission standards Construction and demolition (SPG)

452 views • 22 slides

Thank you for downloading this update. Please feel free to use it for educational purposes.

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

229 views • 8 slides